Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 37.70M | 5.72M | 1.66M | 652.00K | 30.02M | 9.93M |
Gross Profit | 14.67M | 1.89M | -2.38M | -2.72M | 28.64M | -27.55M |
EBITDA | -62.15M | -76.74M | -87.92M | -100.26M | -43.89M | -36.31M |
Net Income | -61.51M | -75.41M | -87.30M | -101.94M | -44.97M | -36.60M |
Balance Sheet | ||||||
Total Assets | 64.37M | 91.05M | 159.56M | 205.32M | 298.58M | 348.99M |
Cash, Cash Equivalents and Short-Term Investments | 50.47M | 72.99M | 130.63M | 161.28M | 268.80M | 335.45M |
Total Debt | 2.02M | 3.41M | 4.20M | 4.90M | 0.00 | 0.00 |
Total Liabilities | 7.35M | 11.42M | 14.86M | 29.17M | 26.80M | 39.13M |
Stockholders Equity | 57.02M | 79.63M | 144.71M | 176.16M | 271.79M | 309.86M |
Cash Flow | ||||||
Free Cash Flow | -55.94M | -60.57M | -81.64M | -106.11M | -65.04M | -34.39M |
Operating Cash Flow | -55.90M | -60.52M | -81.23M | -94.50M | -57.12M | -33.66M |
Investing Cash Flow | 45.78M | -8.51M | 110.86M | 49.44M | -10.44M | -146.32M |
Financing Cash Flow | -106.00K | 787.00K | 48.62M | 171.00K | 1.93M | 330.87M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $35.33M | ― | -277.74% | ― | 536.44% | 63.68% | |
51 Neutral | $7.77B | -0.12 | -39.78% | 2.21% | 22.68% | -1.42% | |
47 Neutral | $49.34M | ― | -73.39% | ― | -27.33% | 34.66% | |
47 Neutral | $40.12M | ― | -90.07% | ― | -32.55% | -15.83% | |
41 Neutral | $35.97M | ― | -312.77% | ― | ― | 61.18% | |
36 Underperform | $40.89M | ― | -47.87% | ― | ― | 18.86% |
On August 5, 2025, Shattuck Labs announced an oversubscribed private placement expected to raise up to approximately $103 million, led by OrbiMed and other investors. The funds will support the clinical development of SL-325 through multiple Phase 2 trials for inflammatory bowel disease and potentially other autoimmune diseases, with operations funded into 2029. The private placement involves shares of common stock and pre-funded warrants, with the proceeds contingent on certain regulatory clearances and conditions.
On July 10, 2025, Shattuck Labs, Inc. held its Annual Meeting of Stockholders where all director nominees were elected and the proposal to ratify KPMG LLP as the independent auditor was approved. The meeting involved voting on the election of Class II Director Nominees and the ratification of KPMG LLP, reflecting shareholder support for the company’s governance and financial oversight.